Moderna (MRNA) closed Thursday down ~17% after phase 3 data was leaked on the company’s personalized cancer vaccine,intismeran autogene, and the Street is offering theories on why.
That data showed that intismeran autogene plus Merck’s (MRK) Keytruda (pembrolizumab) cut the To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Entering text into the input field will update the search result below Quick Insights Phase 3 data showed less robust improvements in recurrent-free and distant metastasis-free survival versus phase 2, with numerically inferior hazard ratios raising concerns about confidence in efficacy.
Analysts are divided: some see it potentially becoming standard, while others note concerns over comparison against changing standards and believe approval would support clinical uptake if label is advantageous. Concerns include the vaccine not providing a transformative change or effective cure, requiring additional tumor sequencing, manufacturing lead time, complex treatment coordination, and high costs